Trastuzumab Emtansine (Ado-Trastuzumab Emtansine) (CAS: 1018448-65-1)
Trastuzumab emtansine (Kadcyla) is an antibody-drug conjugate (ADC) that combines the humanized monoclonal antibody trastuzumab with the cytotoxic drug DM1. It targets the HER2 receptor, which is overexpressed in certain cancers, delivering the cytotoxic agent directly to tumor cells.
Key Features:
- Targeted Therapy: Trastuzumab binds to HER2-expressing cancer cells, directing the cytotoxic drug specifically to the tumor.
- Cytotoxic Payload: DM1 disrupts microtubule function, causing cancer cell death.
- Enhanced Efficacy: The ADC approach delivers higher concentrations of the cytotoxic drug to the tumor, increasing effectiveness and reducing systemic toxicity.
Applications:
- HER2-Positive Metastatic Breast Cancer: Approved for patients previously treated with trastuzumab and a taxane.
- HER2-Positive Gastric Cancer: Investigated for use in patients with advanced gastric cancer expressing HER2.
Handling and Storage:
- Storage: Store at -20°C, away from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.